NOVATO, Calif., July 14 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP), today announced the appointments of Richard L. Franklin, M.D., Ph.D. to the Company's board of directors and Stephen C. Blacklow, M.D., Ph.D. to its scientific advisory board.
Christopher M. Starr, Ph.D., co-founder and CEO of Raptor Pharmaceuticals Corp., stated, "I would like to welcome Drs. Franklin and Blacklow as valuable additions to our board of directors and scientific advisory board, respectively. Dr. Franklin's background is a unique combination of considerable knowledge in areas of biomedical science, particularly in neurology and cancer, as well as years of experience in corporate leadership and finance. We expect to leverage his scientific and investment banking expertise to help guide Raptor's clinical development programs and our corporate strategy towards maximizing stockholder value while addressing critically compelling and unmet medical needs.
"Dr. Blacklow is an internationally recognized scientist," continued Starr. "He has made scientific breakthroughs working with the receptor-associated protein, also known as RAP which is the backbone of Raptor's drug discovery and preclinical efforts. He is expected to provide valuable insight regarding our early-stage programs and adds further expertise to Raptor's already established and distinguished scientific team."
Dr. Franklin has 25 years of experience in the biomedical industry. He is currently Chairman of Synthemed, Inc., a publicly traded medical device company; and DMS Data Systems, an Internet-based information services company. He is also Executive Chairman of Tarix, a subsidiary of medical products company, Phairson, Ltd, where he sits on the board of directors. During his career, Dr. Franklin has founded a healthcare consulting firm, Richard Franklin & Associates, and led the Healthcare Corporate Finance Team at Tucker Anthony, an investment bank. He received a bachelor's degree from Harvard University, an M.A. in mathematics from the University of Washington, a Ph.D. in mathematics from Brandeis University, and an M.D. from Boston University School of Medicine.
Dr. Franklin stated, "As a member of Raptor's board of directors, I look forward to counseling the Company on maximizing the pipeline's potential and delivering value to stockholders. Raptor's scientific expertise and drug discovery capabilities, coupled with a focus on mid-stage clinical studies evaluating novel formulations of existing drugs, strikes the right balance. The drug development risks inherent in preclinical programs are nicely offset by the recently acquired clinical programs focused on reformulating currently approved therapies with known safety profiles and repurposing approved therapies for new indications."
Dr. Blacklow contributes scientific exerptise from academia to Raptor's scientific advisory board. He is an Associate Professor of Pathology and a Director of the M.D. Ph.D. program, basic sciences track, at Harvard Medical School. He also directs a research laboratory at the Brigham and Women's Hospital, a teaching affiliate of Harvard Medical School. Recently, Dr. Blacklow's team determined the structure of the RAP d3 protein complexed with receptor. Over the last ten years, Dr. Blacklow's research team has achieved international recognition for mechanistic and structural studies of low-density lipoprotein or LDL receptor proteins, and for work on the structure and function of human Notch proteins. Dr. Blacklow received his M.D. and Ph.D. in bioorganic chemistry from Harvard University in 1991.
About Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. ("Raptor") is a development-stage
biopharmaceutical company leveraging novel drug-targeting platforms and
enhanced drug formulations to improve treatment outcomes among patients
with liver disorders, infectious diseases, cancer, and various orphan
indications. The Company's clinical division advances internally developed
and in-licensed clinical-stage product candidates towards marketing
approval and commercialization and is currently running clinical trials in
patients with aldehyde dehydrogenase ("ALDH2") deficiency and nephropathic
cystinosis. Raptor's preclinical division bioengineers novel drug
candidates and drug-targeting platforms derived from the human
receptor-associated protein ("RAP") and related proteins to target cancer,
neurodegenerative disorders and infectious diseases.
For additional information, please visit http://www.raptorpharma.com.
FORWARD LOOKING STATEMENTS
This document contains forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements relate to future events or our future results of operation or
future financial performance, including, but not limited to the following
statements: Dr. Franklin's ability to increase stockholder value; Dr.
Blacklow's ability to add value to our preclinical programs; and the
Company's ability to develop, obtain regulatory approval and commercialize
its clinical and preclinical product candidate programs. These statements
are only predictions and involve known and unknown risks, uncertainties and
other factors, which may cause our actual results to be materially
different from these forward-looking statements. Factors which may
significantly change or prevent our forward looking statements from
fruition include that we may be unsuccessful in developing any products or
acquiring products; that our technology may not be validated as we progress
further and our methods may not be accepted by the scientific community;
that we are unable to retain or attract key employees whose knowledge is
essential to the development of our products; that unforeseen scientific
difficulties develop with our process; that our patents are not sufficient
to protect essential aspects of our technology; that competitors may invent
better technology; that our products may not work as well as hoped or
worse, that our products may harm recipients; and that we may not be able
to raise sufficient funds for development or working capital when we
require it. As well, our products may never develop into useful products
and even if they do, they may not be approved for sale to the public. We
caution readers not to place undue reliance on any such forward-looking
statements, which speak only as of the date they were made. Certain of
these risks, uncertainties, and other factors are described in greater
detail in our filings from time to time with the Securities and Exchange
Commission (the "SEC"), which we strongly urge you to read and consider,
including our Registration Statement on Form SB-2, as amended, that was
declared effective on July 10, 2006; our annual report on Form 10-KSB filed
with the SEC on November 14, 2007; and our Form 10-QSB filed with the SEC
on July 9, 2008, all of which are available free of charge on the SEC's web
site at http://www.sec.gov. Subsequent written and oral forward-looking
statements attributable to us or to persons acting on our behalf are
expressly qualified in their entirety by the cautionary statements set
forth in our reports filed with the SEC. We expressly disclaim any intent
or obligation to update any forward-looking statements.
For more information, please contact:
The Ruth Group
Sara Ephraim (investors) Janine McCargo (media)
(646) 536-7002 (646) 536-7033
|SOURCE Raptor Pharmaceuticals Corp.|
Copyright©2008 PR Newswire.
All rights reserved